HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D

被引:165
作者
Cozzolino, M [1 ]
Vidal, M [1 ]
Arcidiacono, MV [1 ]
Tebas, P [1 ]
Yarasheski, KE [1 ]
Dusso, AS [1 ]
机构
[1] Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA
关键词
protease inhibitors; vitamin D; bone mineral metabolism; cytochrome P450;
D O I
10.1097/00002030-200303070-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A high prevalence of bone demineralization occurs in people living with HIV/AIDS. The contribution of HIV itself and its treatment is still unclear. Protease inhibitors (Pis) are potent inhibitors of the cytochrome P450 enzyme system. Three cytochrome P450 mixed function oxygenases control serum levels of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) which is responsible for vitamin D-3 actions in target tissues including bone. The 25- and la-hydroxylases regulate 1,25(OH)(2)D-3 synthesis and 24-hydroxylase 1,25(OH)(2)D-3 catabolism. Objective: To assess whether HIV-protease inhibitors (ritonavir, indinavir, nelfinavir) impair the activity of the main enzymes involved in 1,25(OH)(2)D-3 homeostasis. Design and methods: Studies were conducted in the human hepatocyte (H3B)- and monocyte (THP-1) cell lines, expressing 25-hydroxylase and 1alpha-hydroxylase, respectively. The 24-hydroxylase expression was induced in macrophages by exposure to 1,25(OH)(2)D-3. Conversion rates of vitamin D-3 to 25-hydroxyvitamin D-3 [25(OH)D-3]; 25(OH)D-3 to 1,25(OH)(2)D-3 or 24,25(OH)(2)D-3, and 1,25(OH)(2)D-3 degradation were quantified in untreated and HIV-PI-treated cells after C-18-cartridge extraction and high-performance liquid chromatography purification of 25(OH)D-3- 24,25(OH)(2)D-3-and 1,25(OH)(2)D-3 fractions. Results: The Pis impair hepatocyte 25(OH)D-3-and macrophage 1,25(OH)(2)D-3 synthesis in a reversible, dose-dependent manner. Furthermore, Pis inhibit 1,25(OH)(2)D-3-degradation in macrophages with lower potency than that elicited on 1alpha-hydroxylase. Thus, reduced macrophage 1,25(OH)(2)D-3 production is the net effect of PIs action. Conclusions: In intact cells in vitro, HIV-PIs markedly suppress the activities of 25-and la-hydroxylase, which are critical in 1,25(OH)(2)D-3 synthesis, while exerting mild inhibition of 24-hydroxylase, responsible for 1,25(OH)(2)D-3 catabolism. If Pis elicit a similar potency in inhibiting these critical steps for 1,25(OH)(2)D-3 homeostasis in vivo, defective 1,25(OH)(2)D-3 production could contribute to the bone demineralization in HIV patients. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:513 / 520
页数:8
相关论文
共 37 条
[1]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[2]   Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [J].
Brinkman, K ;
ter Hofstede, HJM ;
Burger, DM ;
Smeitinkt, JAM ;
Koopmans, PP .
AIDS, 1998, 12 (14) :1735-1744
[3]   Vitamin D [J].
Brown, AJ ;
Dusso, A ;
Slatopolsky, E .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 277 (02) :F157-F175
[4]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[5]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[6]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[7]   Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy [J].
Carr, A ;
Miller, J ;
Eisman, JA ;
Cooper, DA .
AIDS, 2001, 15 (06) :703-709
[8]  
Carr A, 1998, LANCET, V351, P1736, DOI 10.1016/S0140-6736(05)77775-8
[9]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[10]  
DUSSO A, 1994, SEMIN NEPHROL, V14, P144